Εξειδίκευση τύπου :	Άρθρο σε επιστημονικό περιοδικό
Τίτλος:	Senolytics and senomorphics: Natural and synthetic therapeutics in the treatment of aging and chronic diseases
Δημιουργός/Συγγραφέας:	Lagoumtzi, Sofia M [EL] Χονδρογιάννη, Νίκη[EN] Chondrogianni, Niki
Εκδότης:	Elsevier
Ημερομηνία:	2021-08-01
Γλώσσα:	Αγγλικά
ISSN:	08915849
DOI:	10.1016/j.freeradbiomed.2021.05.003
Άλλο:	33989756
Περίληψη:	Cellular senescence is a heterogeneous process guided by genetic, epigenetic and environmental factors, characterizing many types of somatic cells. It has been suggested as an aging hallmark that is believed to contribute to aging and chronic diseases. Senescent cells (SC) exhibit a specific senescence-associated secretory phenotype (SASP), mainly characterized by the production of proinflammatory and matrix-degrading molecules. When SC accumulate, a chronic, systemic, low-grade inflammation, known as inflammaging, is induced. In turn, this chronic immune system activation results in reduced SC clearance thus establishing a vicious circle that fuels inflammaging. SC accumulation represents a causal factor for various age-related pathologies. Targeting of several aging hallmarks has been suggested as a strategy to ameliorate healthspan and possibly lifespan. Consequently, SC and SASP are viewed as potential therapeutic targets either through the selective killing of SC or the selective SASP blockage, through natural or synthetic compounds. These compounds are members of a family of agents called senotherapeutics divided into senolytics and senomorphics. Few of them are already in clinical trials, possibly representing a future treatment of age-related pathologies including diseases such as atherosclerosis, osteoarthritis, osteoporosis, cancer, diabetes, neurodegenerative diseases such as Alzheimer's disease, cardiovascular diseases, hepatic steatosis, chronic obstructive pulmonary disease, idiopathic pulmonary fibrosis and age-related macular degeneration. In this review, we present the already identified senolytics and senomorphics focusing on their redox-sensitive properties. We describe the studies that revealed their effects on cellular senescence and enabled their nomination as novel anti-aging agents. We refer to the senolytics that are already in clinical trials and we present various adverse effects exhibited by senotherapeutics so far. Finally, we discuss aspects of the senotherapeutics that need improvement and we suggest the design of future senotherapeutics to target specific redox-regulated signaling pathways implicated either in the regulation of SASP or in the elimination of SC.
Τίτλος πηγής δημοσίευσης:	Free radical biology & medicine
Τόμος/Κεφάλαιο:	171
Σελίδες:	169-190
Θεματική Κατηγορία:	[EL] Χημική Βιολογία[EN] Chemical Biology [EL] Βιοχημεία[EN] Biochemistry [EL] Φαρμακευτική τεχνολογία[EN] Pharmaceutical technology [EL] Φαρμακευτική χημεία[EN] Pharmaceutical chemistry
Λέξεις-Κλειδιά:	Aging Age-related diseases Cellular senescence Natural compounds Senescence-associated secretory phenotype (SASP) Senolytics Senomorphics Cellular Senescence Chronic Disease Humans Longevity Neurodegenerative Diseases
Κάτοχος πνευματικών δικαιωμάτων:	Copyright © 2021 Elsevier Inc. All rights reserved.
Ηλεκτρονική διεύθυνση στον εκδότη (link):	https://doi.org/10.1016/j.freeradbiomed.2021.05.003
Ηλεκτρονική διεύθυνση περιοδικού (link) :	https://www.sciencedirect.com/journal/free-radical-biology-and-medicine
Εμφανίζεται στις συλλογές:	Ινστιτούτο Χημικής Βιολογίας - Επιστημονικό έργο